Understanding chemico-physical status from API to formulation gives better performance than original drugs.
Name | Active Ingredient / Formulation | Strength | Indication | Characteristics |
---|---|---|---|---|
Genexol® PM Inj. |
Paclitaxel/Lyo. | 30mg, 100mg |
Breast cancer, NSCLC, Ovarian cancer |
|
![]() Nanoxel® M Inj. |
Docetaxel/Lyo. | 20mg, 80mg |
Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer |
|
![]() Genexol® Inj. |
Paclitaxel/Liq. | 30mg, 100mg, 300mg |
Breast cancer, NSCLC, Ovarian cancer |
|
![]() Docetaxel Inj. |
Docetaxel/Liq. | 20mg, 80mg, 140mg, 160mg |
Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer |
|
![]() Zolenic® Inj. |
Zoledronic acid/Liq. | 4mg | Bone complications of cancer |
|
![]() Nexatin® Inj. |
Oxaliplatin/Liq. | 50mg, 100mg, 200mg |
Colorectal cancer, Gastric cancer |
|
![]() Pemed® Inj. |
Pemetrexed/Lyo. & Liq. | 100mg, 500mg, 1,000mg |
NSCLC |
|
Crabcitabin® Inj. |
Gemcitabine/Liq. | 200mg, 1,000mg |
Pancreas, Lung, Ovary, and Breast |
|
![]() Protezomib® Inj. |
Bortezomib/Lyo. | 3.5mg, 2.5mg |
Mantle cell lymphoma, Multiple Myeloma |
|
Palonosetron Inj. |
Palonosetron/Liq | 0.075mg, 0.25mg |
Antiemetics |
|
Emestop® Inj. |
Ramosetron/Liq | 0.3mg | Antiemetics |
|
Emestop® FDT |
Ramosetron/Tablet | 0.1mg | Antiemetics |
|
![]() Lenalid® Tab |
Lenalidomide/Tab | 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg |
Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Mantle Cell Lymphoma (MCL) |
|
![]() Azalid® |
Azacitidine/Lyo. | 150mg | Myelodysplastic syndrome(MDS), Acute myeloid leukemia (AML), Chronic bone mineral composition leukemia (CMML) |
|
![]() Decilid® |
Decitabine/Lyo. | 40mg | Myelodysplastic syndrome(MDS), Chronic bone mineral composition leukemia (CMML) |
|